CAST10 Archives

May 2021

CAST10@LISTSERV.UMD.EDU

Options: Use Monospaced Font
Show HTML Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Georgakis, Christos" <[log in to unmask]>
Reply To:
Georgakis, Christos
Date:
Tue, 11 May 2021 02:04:15 +0000
Content-Type:
multipart/alternative
Parts/Attachments:
text/plain (7 kB) , text/html (53 kB)
View this email in your browser<https://mailchi.mp/d64eb1b19227/announcing-fipse-4960679?e=d5eafbfe1a>
Register to Attend FIPSE 4.5
First Session for USA & Europe on June 22, 2021
16:00-18:00  London Time
Register HERE<https://fi-inPSE.us7.list-manage.com/track/click?u=dfd008ceefe87cb6dce03e784&id=bf19eae981&e=d5eafbfe1a>
Second Session for Europe & Australasia on June 24, 2021
09:00-11:00  London Time
Register HERE<https://fi-inPSE.us7.list-manage.com/track/click?u=dfd008ceefe87cb6dce03e784&id=45ffaf374e&e=d5eafbfe1a>


[https://mcusercontent.com/dfd008ceefe87cb6dce03e784/images/7160cf4b-3127-4832-aa63-a2946c94cf13.jpg]
FIPSE 4.5 Webinar
The FIPSE Conference Series
and Vaccine Manufacturing


The agenda of this webinar is as follows:

  1.  The mission of the FIPSE conferences (14 min)
     *   Christos Georgakis, Tufts U., FIPSE Trustee & President
  2.  FIPSE 1 to 4: What has been tried and achieved (14 min)
     *   Dominique Bonvin, EPFL,  FIPSE Trustee & Treasurer
  3.  Presentation on: "Quality by Digital Design for vaccine process development and manufacturing" (30 min)
     *   Cleo Kontoravdi, Imperial College
  4.  Panel discussion (45 min)
     *   Claire Adjiman, Imperial College  FIPSE Trustee, Panel Chair,
     *   Cleo Kontoravdi, Imperial College, Panelist
     *   Cristiana Campa, GlaxoSmithKline, Panelist
     *   Christos Varsakelis, Janssen Pharmaceutical, Panelist
     *   Julia O’Neill, Moderna, Panelist (only in the first session)


Biographical Sketches of Main Speaker and Panelists

[https://mcusercontent.com/dfd008ceefe87cb6dce03e784/images/15cbd017-81d9-4681-8fda-b5b219a3e4b5.jpg]
Cleo Kontoravdi is Reader in Biosystems Engineering at the Department of Chemical Engineering, Imperial College London. Her research focuses on the application of systems engineering principles to bioprocessing. A large part of it is dedicated to understanding what process factors control the quality of therapeutic protein products and to efforts of controlling these to achieve better production and quality targets. To achieve this, her group follows a holistic approach that combines experimentation with model-based design and optimisation tools, which is an excellent vehicle for the   industrial implementation of Quality by Design. She holds M.Eng. and Ph.D. degrees in Chemical Engineering from Imperial College London.

[https://mcusercontent.com/dfd008ceefe87cb6dce03e784/images/d1942f74-e927-4b64-9bde-032668afa8af.jpg]
Cristiana Campa, Ph.D., is currently a Technical R&D Advisor and Fellow at GSK Vaccines, with more than 20 years of experience in biologics and related analytical and development strategies gained in different universities and companies. She joined Novartis Vaccines in 2006, focusing on the development, validation, and transfer of analytical methods for the release and characterization of several vaccine products, first as a senior manager and then as Head of Analytical Development, Italy. Since 2012, Cristiana has worked on Quality by Design (QbD) principles implementation for vaccines. After the acquisition of Novartis Vaccines by GSK in 2015, she has been the Head of QbD Integration. Until June 2018, the Head of Science and Development Practices in Technical R&D, covering QbD implementation, Knowledge Management, and Development roadmaps.

[https://mcusercontent.com/dfd008ceefe87cb6dce03e784/images/e47bbc92-b084-4390-b49c-6e493faba068.jpg]
Christos Varsakelis leads the AI/ML compound profiling team in the Janssen Pharmaceutical Companies to accelerate drug discovery & development timelines. Before joining Janssen, Christos was a Senior Manager of Global Analytics & Innovation in GSK Vaccines focusing on in silico process development. Besides working in the pharmaceutical industry, Christos has an accumulated professional experience that spans Geoconsulting, the stock market, and the chemical industry. Christos holds a Ph.D. in fluid mechanics at UCLouvain in Belgium. He also holds a B.A. in Mathematics from the Aristotle University of Thessaloniki, Greece, and an M.Sc. in Applied Mathematics from ETH Zurich, Switzerland. His motto is innovation = cash.

[https://mcusercontent.com/dfd008ceefe87cb6dce03e784/images/28be1624-80bf-faf1-1bed-6641143198f1.jpg]
Julia O’Neill is a Distinguished Fellow and leads the Modeling and Statistics team for Moderna as a Technical Development Leadership Team member. O’Neill worked at Merck as Senior Scientific Fellow (Statistics) in Regulatory & Analytical Sciences. She was also Director in Global Technical Operations, with a primary focus on vaccines and biologics. She has over 30 years of experience bridging statistics and chemical engineering in the pharmaceutical and chemical industries. Her education synthesizes statistics and engineering, with an MS in Statistics from the University of Wisconsin and a BS in Chemical Engineering from the University of Maine.


This is a FREE webinar on Zoom
Registration is Required
It is given on two consecutive dates to accommodate audiences in the US, Europe, and Australasia. Besides having a chance to explore the PSE challenges of vaccine manufacturing, you will also learn about the value of the FIPSE conference series.

       Session A:  Register here<https://fi-inPSE.us7.list-manage.com/track/click?u=dfd008ceefe87cb6dce03e784&id=d72018b10b&e=d5eafbfe1a>
June 22 for audiences in the USA and Europe

  *   11:00 – 13:00     Boston Time
  *   17:00 – 19:00     Central European time
  *   16:00 – 18:00     London Time
  *   08:00 – 10:00     LA Time

      Session B: Register here<https://fi-inPSE.us7.list-manage.com/track/click?u=dfd008ceefe87cb6dce03e784&id=bc0fc810ae&e=d5eafbfe1a>
June 24 for audiences in Europe and Australasia,

  *   09:00 – 11:00     London Time
  *   10:00 – 12:00     Central European time
  *   16:00 – 18:00     Beijing Time
  *   17:00 – 19:00     Seoul/Tokyo Time
  *   18:00 – 20:00     Sydney Time
  *   20:00 – 22:00     Auckland Time


Copyright © 2021 FIPSE, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
FIPSE
170 Collins Rd
Waban, MA 02468-2204

Add us to your address book<https://fi-inPSE.us7.list-manage.com/vcard?u=dfd008ceefe87cb6dce03e784&id=a416e837e2>


Want to change how you receive these emails?
You can update your preferences<https://fi-inPSE.us7.list-manage.com/profile?u=dfd008ceefe87cb6dce03e784&id=a416e837e2&e=d5eafbfe1a&c=952c4a16c7> or unsubscribe from this list<https://fi-inPSE.us7.list-manage.com/unsubscribe?u=dfd008ceefe87cb6dce03e784&id=a416e837e2&e=d5eafbfe1a&c=952c4a16c7>.






This email was sent to [log in to unmask]<mailto:[log in to unmask]>
why did I get this?<https://fi-inPSE.us7.list-manage.com/about?u=dfd008ceefe87cb6dce03e784&id=a416e837e2&e=d5eafbfe1a&c=952c4a16c7>    unsubscribe from this list<https://fi-inPSE.us7.list-manage.com/unsubscribe?u=dfd008ceefe87cb6dce03e784&id=a416e837e2&e=d5eafbfe1a&c=952c4a16c7>    update subscription preferences<https://fi-inPSE.us7.list-manage.com/profile?u=dfd008ceefe87cb6dce03e784&id=a416e837e2&e=d5eafbfe1a&c=952c4a16c7>
FIPSE · 170 Collins Rd · Waban, MA 02468-2204 · USA

[Email Marketing Powered by Mailchimp]<http://www.mailchimp.com/email-referral/?utm_source=freemium_newsletter&utm_medium=email&utm_campaign=referral_marketing&aid=dfd008ceefe87cb6dce03e784&afl=1>


ATOM RSS1 RSS2